Zymeworks Announces China NMPA Acceptance of Biologics License Application for Zanidatamab for Second-Line Treatment of Biliary Tract Cancer
10 juin 2024 06h00 HE
|
Zymeworks Inc.
Pursuant to the terms of the licensing agreement between Zymeworks and BeiGene, Zymeworks is entitled to receive an $8 million milestone payment from BeiGene and remains eligible to receive up to $164...
Zymeworks Announces Participation in Upcoming Investor Conferences
28 mai 2024 06h30 HE
|
Zymeworks Inc.
VANCOUVER, British Columbia, May 28, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional...
Zymeworks Provides Corporate Update and Reports First Quarter 2024 Financial Results
02 mai 2024 16h05 HE
|
Zymeworks Inc.
Reported $420.5 million in cash resources as of March 31, 2024, which when combined with certain anticipated regulatory milestone payments provides projected cash runway into 2H 2027Completion of...
Zymeworks Announces Participation in Upcoming Investor Conferences
30 avr. 2024 06h00 HE
|
Zymeworks Inc.
VANCOUVER, British Columbia, April 30, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional...
Zymeworks To Report First Quarter 2024 Financial Results and Host Conference Call on May 2, 2024
11 avr. 2024 06h00 HE
|
Zymeworks Inc.
VANCOUVER, British Columbia, April 11, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional...
Zymeworks Presents New Data from Multiple Preclinical Development Programs at 2024 American Association for Cancer Research Annual Meeting
08 avr. 2024 06h00 HE
|
Zymeworks Inc.
VANCOUVER, British Columbia, April 08, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional...
Zymeworks Announces Appointment of Dr. Neil Gallagher to its Board of Directors
28 mars 2024 06h00 HE
|
Zymeworks Inc.
VANCOUVER, British Columbia, March 28, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional...
Zymeworks Announces Participation in Upcoming Investor Conferences
27 mars 2024 06h00 HE
|
Zymeworks Inc.
VANCOUVER, British Columbia, March 27, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional...
Zymeworks Reports Fourth Quarter and Full Year 2023 Financial Results
06 mars 2024 16h09 HE
|
Zymeworks Inc.
Reported $456.3 million in cash resources as of December 31, 2023, which when combined with certain anticipated regulatory milestone payments provides projected cash runway into 2H 2027Initiation of...
Zymeworks to Present Preclinical Data on Antibody-Drug Conjugate and Multispecific Platforms at the American Association for Cancer Research Annual Meeting
05 mars 2024 16h30 HE
|
Zymeworks Inc.
Five abstracts accepted for poster presentation highlight company’s differentiated antibody-drug conjugate and multispecific antibody clinical product candidatesStrong preclinical activity across...